Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings Results

Corvus Pharmaceuticals (NASDAQ:CRVS) issued its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01), FiscalAI reports.

Here are the key takeaways from Corvus Pharmaceuticals’ conference call:

• Soquelitinib showed strong clinical activity in cohort 4 of the atopic dermatitis (AD) Phase 1 trial — mean EASI reduction 72% vs 40% placebo and 75% of patients achieved EASI‑75 at 8 weeks — with most responders maintaining benefit during extended off‑treatment follow‑up.
• Biomarker data support a novel immune‑rebalancing mechanism (increased circulating Tregs, reductions in IL‑4/IL‑5/IL‑17 and JAK‑STAT signaling), which the company says may explain the durability and broaden applicability across inflammatory and immune diseases.
• Balance sheet strengthened by an upsized public offering: pro forma cash of ~$246 million (including $189M net proceeds) which management says extends the cash runway into Q2 2028 and covers planned milestones.
• Clinical development is advancing across multiple programs with a Phase 3 PTCL trial enrolling (interim analysis later this year), a 200‑patient Phase 2 AD study initiated (readout mid‑2027), China Phase 1b/2 results expected late this year, and planned Phase 2 trials in hidradenitis suppurativa and asthma.
• Costs and losses rose as R&D spending increased (FY2025 R&D $33.7M versus $19.4M in 2024) and the company reported continued net losses, meaning future value remains dependent on successful clinical readouts and execution.

Corvus Pharmaceuticals Trading Down 4.3%

Shares of CRVS stock traded down $0.69 during trading hours on Friday, reaching $15.32. 160,309 shares of the company’s stock were exchanged, compared to its average volume of 3,915,635. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -29.21 and a beta of 0.78. Corvus Pharmaceuticals has a fifty-two week low of $2.54 and a fifty-two week high of $26.95. The stock’s 50 day moving average is $16.30 and its 200-day moving average is $10.47.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CRVS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Friday. Oppenheimer boosted their price objective on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Jefferies Financial Group upped their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Barclays lifted their price target on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, HC Wainwright boosted their price target on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $31.80.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $27,000. Russell Investments Group Ltd. purchased a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Truvestments Capital LLC raised its position in shares of Corvus Pharmaceuticals by 86.1% in the 4th quarter. Truvestments Capital LLC now owns 10,257 shares of the company’s stock valued at $79,000 after purchasing an additional 4,744 shares during the last quarter. Captrust Financial Advisors purchased a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $85,000. Finally, Fox Run Management L.L.C. acquired a new position in Corvus Pharmaceuticals during the 4th quarter valued at approximately $86,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.